Cell analysis company Mission Bio aiming to scale with $70M series C

Two years after generating its first revenues, single-cell analysis and profiling company Mission Bio hopes to use its new $70 million series C round to scale its commercial operations broadly to help its clients identify biomarkers and stratify patients in clinical trials.

The South San Francisco company markets its Tapestri analysis platform to biopharmas, cancer research centers and other laboratory operators. It’s sold as instruments and consumables, co-founder and CEO Charlie Silver told BioCentury...